Aktienanalyse zu PepGen Inc (PEPG)PEPGPepGen Inc

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

While PepGen Inc is currently trading at $2.35, significantly below its 52-week high of $7.80, the RSI is at 32.63, indicating oversold conditions. However, the company has a negative forward P/E ratio of 0 and has reported consistent losses, with a net income of -$17.76 million in Q1 2026. The upcoming data from the 10 mg/kg FREEDOM2 cohort in H2 2026 could be a potential catalyst, but current financial instability and regulatory challenges pose risks. Therefore, it is advisable to hold rather than buy at this moment.